A Combined Phase I & II Trial of Intravesicular Abraxane, a Nanoparticle Albumin-Bound Paclitaxel, for Treatment-Refractory Transitional Cell Carcinoma of the Urinary Bladder.

Trial Profile

A Combined Phase I & II Trial of Intravesicular Abraxane, a Nanoparticle Albumin-Bound Paclitaxel, for Treatment-Refractory Transitional Cell Carcinoma of the Urinary Bladder.

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Paclitaxel (Primary)
  • Indications Bladder cancer
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 05 Nov 2012 Planned end date changed from 1 Jul 2012 to 1 Jun 2013 as reported by ClinicalTrials.gov.
    • 09 Feb 2012 Additional lead trial centre identified as reported by ClinicalTrials.gov.
    • 02 Aug 2011 Company added as trial sponsor as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top